Table 3.
MMSE score and MCI Prevalence According to SUA quartiles by gender and hyperuricemia
| SUA quartiles by gender and hyperuricemia | ||||||
|---|---|---|---|---|---|---|
| Q1 | Q2 | Q3 | Q4 | P trend | total | |
| Participants without hyperuricemia | ||||||
| MMSE score | ||||||
| Male | 26.9 ± 3.9 | 27.0 ± 4.0 | 27.1 ± 3.4 | 27.2 ± 3.7 | 0.038 | 27.0 ± 3.8 |
| Female | 26.3 ± 3.8 | 26.5 ± 4.1 | 27.0 ± 3.9 | 27.1 ± 3.2 | 0.048 | 26.7 ± 3.8 |
| Subtotal | 26.6 ± 3.9 | 26.8 ± 4.1 | 27.0 ± 3.7 | 27.1 ± 3.4 | 0.031 | 26.8 ± 3.8 |
| Prevalence of MCI | ||||||
| Male | 28(15.7) | 23(13.7) | 24(13.6) | 21(11.9) | 0.039 | 96(13.7) |
| Female | 68(25.8) | 52(20.1) | 39(14.8) | 36(13.6) | 0.008 | 195(18.6) |
| Subtotal | 96(20.9) | 75(16.7) | 63(15.2) | 57(13.7) | 0.030 | 291(16.6) |
| Participants with hyperuricemia | ||||||
| MMSE score | ||||||
| Male | 27.8 ± 3.2 | 27.7 ± 2.5 | 27.7 ± 2.8 | 27.5 ± 2.2 | 0.965 | 27.7 ± 2.6 |
| Female | 26.7 ± 3.6 | 27.4 ± 2.7 | 27.2 ± 4.1 | 26.5 ± 3.4 | 0.549 | 27.0 ± 3.5 |
| Subtotal | 27.2 ± 3.4 | 27.5 ± 2.5 | 27.3 ± 3.6 | 27.0 ± 3.1 | 0.772 | 27.2 ± 3.1 |
| Prevalence of MCI | ||||||
| Male | 5(13.5) | 3(8.1) | 4(10.8) | 1(2.7) | 0.155 | 13(8.8) |
| Female | 9(18.8) | 7(13.0) | 4(7.8) | 11(21.6) | 0.854 | 31(15.2) |
| Subtotal | 14(16.5) | 10(11.0) | 8(9.1) | 12(13.6) | 0.526 | 44(12.5) |